Skip to content

In the BioHarmony Drug Report Database

Tobramycin

Bethkis, Kitabis Pak, Tobi, Tobi Podhaler, Tobrex, Tobramycin PARI, Vantobra (tobramycin) is a small molecule pharmaceutical. Tobramycin was first approved as Bethkis on 1982-01-01. It is used to treat bacterial eye infections, bacterial infections, central nervous system infections, infectious bone diseases, and infectious skin diseases amongst others in the USA. It has been approved in Europe to treat cystic fibrosis and respiratory tract infections. Tobrex's patents are valid until 2030-11-04 (FDA).
Trade Name Tobi Podhaler, Tobramycin PARI, Vantobra
Common Name Tobramycin
Indication bacterial eye infections, bacterial infections, central nervous system infections, cystic fibrosis, infectious bone diseases, infectious skin diseases, intraabdominal infections, pseudomonas infections, respiratory tract infections, staphylococcal infections, urinary tract infections
Drug Class Antibiotics (Streptomyces strains)
Tobramycin
Get full access now